The U.S. Food and Drug Administration approved Eli Lilly’s Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.
Baxter International Inc. announced the U.S. Food and Drug Administration approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection).
Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.
Novo Nordisk’s diabetes drug Victoza (liraglutide) earned approval from the U.S. FDA for an expanded indication for use in children ages 10 to 17 years who have type 2 diabetes.
Janssen Presents Landmark Data From Invokana Study
Black Box Warning, Cardiovascular Deaths, Cardiovascular Events, Chronic Kidney Disease, Clinical Data, Clinical Trials, Diabetes, FDA, Glycemic Control, Kidney Failure, Lower limb amputations, R&D, SGLT2 Inhibitors, Supplemental New Drug Application (sNDA), Type 2 DiabetesJanssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
